Leap Therapeutics Stock Analysis

Leap Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.4. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Leap Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 3.98. The firm had not issued any dividends in recent years. Leap Therapeutics had 1:10 split on the 21st of June 2023. Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. To find out more about Leap Therapeutics contact the company at 617 714 0360 or learn more at https://www.leaptx.com.

Leap Therapeutics Investment Alerts

Leap Therapeutics Upcoming and Recent Events

Leap Largest EPS Surprises

View All Earnings Estimates

Leap Stock Institutional Investors

Note, although Leap Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Leap Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Leap Therapeutics's market, we take the total number of its shares issued and multiply it by Leap Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Leap Profitablity

Management Efficiency

Leap Therapeutics has return on total asset (ROA) of (0.7503) % which means that it has lost $0.7503 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3682) %, meaning that it created substantial loss on money invested by shareholders. Leap Therapeutics' management efficiency ratios could be used to measure how well Leap Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.17 in 2024. Return On Capital Employed is likely to rise to -1.37 in 2024. At this time, Leap Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 45.2 M in 2024.

Technical Drivers

As of the 23rd of April, Leap Therapeutics secures the Mean Deviation of 4.55, downside deviation of 4.83, and Risk Adjusted Performance of 0.0284. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Leap Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Leap Therapeutics, which can be compared to its peers in the industry. Please verify Leap Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Leap Therapeutics is priced some-what accurately, providing market reflects its recent price of 3.2 per share. Given that Leap Therapeutics has jensen alpha of 0.0403, we recommend you to check Leap Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Leap Therapeutics Price Movement Analysis

Leap Therapeutics Insider Trading Activities

Leap Therapeutics Predictive Daily Indicators

Leap Therapeutics Corporate Filings

Leap Therapeutics Forecast Models

Leap Therapeutics' time-series forecasting models are one of many Leap Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Leap Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Leap Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Leap shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Leap Therapeutics. By using and applying Leap Stock analysis, traders can create a robust methodology for identifying Leap entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Leap analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Leap analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Leap Therapeutics stock analysis indicators help investors evaluate how Leap Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Leap Therapeutics shares will generate the highest return on investment. By understating and applying Leap Therapeutics stock analysis, traders can identify Leap Therapeutics position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Leap Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Leap Therapeutics. If investors know Leap will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Leap Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Leap Therapeutics is measured differently than its book value, which is the value of Leap that is recorded on the company's balance sheet. Investors also form their own opinion of Leap Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Leap Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Leap Therapeutics' market value can be influenced by many factors that don't directly affect Leap Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Leap Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Leap Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Leap Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.